HARS1/Jo-1 anticorps (C-Term)

N° du produit ABIN7180180

Détail du produit anti-HARS1/Jo-1 anticorps

Antigène: HARS1/Jo-1 (HARS1) (Histidyl-tRNA Synthetase (HARS1))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HARS1/Jo-1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Réactivité croisée: Humain, Souris

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogène: Synthesized peptide derived from C-terminal of Human HARS.

Isotype: IgG

Information d'application

Indications d'application: WB:1:500-1:3000, IF:1:100-1:500,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur HARS1/Jo-1

Antigène: HARS1/Jo-1 (HARS1) (Histidyl-tRNA Synthetase (HARS1))

Autre désignation: HARS (HARS1 Produits)

Synonymes: anticorps HRS, anticorps USH3B, anticorps MMHRS, anticorps Dnd1, anticorps HARSL, anticorps histidyl-tRNA synthetase, anticorps HARS, anticorps Hars

Sujet:

Background: Defects in HARS are a cause of Usher syndrome type 3B (USH3B). USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life. Belongs to the class-II aminoacyl-tRNA synthetase family.

Raben N., Nucleic Acids Res. 20:1075-1081(1992).
Tsui F.W.L., Nucleic Acids Res. 15:3349-3367(1987).
Tsui H.W., Gene 131:201-208(1993).

Aliases: cytoplasmic antibody, EC 6.1.1.21 antibody, FLJ20491 antibody, HARS antibody, HisRS antibody, Histidine tRNA ligase, cytoplasmic antibody, histidine translase antibody, Histidine tRNA ligase antibody, Histidine--tRNA ligase antibody, Histidyl tRNA synthetase antibody, Histidyl-tRNA synthetase antibody, HRS antibody, Human histidyl tRNA synthetase homolog (HO3) mRNA complete cds antibody, SYHC_HUMAN antibody, USH3B antibody

UniProt: P12081